Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02298335|
Recruitment Status : Unknown
Verified August 2016 by Zhi-Hong Liu, M.D., Nanjing University School of Medicine.
Recruitment status was: Recruiting
First Posted : November 21, 2014
Last Update Posted : August 11, 2016
|Condition or disease||Intervention/treatment||Phase|
|Nephrotic Syndrome，Idiopathic||Drug: prednisone||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||235 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Observational Study to Assess the Efficacy an Safety of Glucocorticoid Therapy in the Treatment of Adult Idiopathic Nephrotic Syndrome|
|Study Start Date :||June 2014|
|Estimated Primary Completion Date :||March 2017|
|Estimated Study Completion Date :||June 2018|
First,full-dose induction period, then protracted tapering period.
Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
- the cumulative complete remission rate of 8-weeks full-dose induction protocol [ Time Frame: 8 weeks ]
- the relapse rate of complete remission participants protracted tapering protocol [ Time Frame: 66 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02298335
|Contact: Haitao Zhang, MDemail@example.com|
|Research Institute of Nephrology||Recruiting|
|Nanjing, Jiangsu, China, 210000|
|Contact: Haitao Zhang, MD 86-25-80861312 firstname.lastname@example.org|
|Contact: Minlin Zhou, MD 86-25-80863791 email@example.com|
|Study Chair:||Zhihong Liu, MD||Nanjing University School of Medicine|